Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030

Published by Roots Analysis Product code 929147
Published Content info 318 Pages
Delivery time: 1-2 business days
Price
Back to Top
Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030
Published: March 31, 2020 Content info: 318 Pages
Description

Overview:

Oligonucleotides have a wide range of applications in medical science. In basic research and diagnostics, these are indispensable to contemporary molecular testing and analytical protocols (such as the polymerase chain reaction (PCR), and DNA sequencing), genomic library construction and artificial gene synthesis. In fact, amid the ongoing coronavirus pandemic, several oligonucleotide manufacturers have started offering critical oligonucleotide chemistries, controls and components for the delivery of COVID-19 detection kits at scale. As therapeutic agents, oligonucleotides are known to be associated with certain unique features, such as high selectivity and potency (similar to biologics), and differentiated pharmacology, which further augment their drug-like properties. Moreover, there are established rational approaches that can be leveraged to design oligonucleotide leads, and the overall cost of such drug development initiatives, compared to conventional small molecule drugs and biologics, is reportedly lower. Vitravene® was the first antisense oligonucleotide-based product in 1998. At present, eight oligonucleotide-based drugs are available in the market, namely (in reverse chronological order of year of approval) GIVLAARI™ (2019), ONPATTRO® (2018), TEGSEDI™ (2018), SPINRAZA® (2016), EXONDYS 51® (2016), DEFITELIO® (2016), KYNAMRO™ (2013), and MACUGEN® (2004). Further, more than 200 unique oligonucleotide-based product candidates are currently being evaluated in various preclinical / clinical phases of development.

According to experts, the use of oligonucleotides as a treatment option is limited due to complexities associated with the synthesis of such compounds. Similar to small molecule drugs, oligonucleotides can be manufactured via chemical synthesis methods, solid phase synthesis being one of the most popular approaches used. However, there are certain technical requirements (chemical modification-related expertise) and complex analytical expertise required for development, synthesis and purification of this class of molecules. As a result, oligonucleotide manufacturing has emerged as a much sought-after capability within the modern biopharmaceutical industry. Presently, a significant proportion of the existing expertise and manufacturing capacity for oligonucleotides belong to contract service providers. In fact, most researchers and many therapy / diagnostic developers have demonstrated preference to outsource oligonucleotide manufacturing operations, instead of building in-house capabilities for the same. Several big pharma companies, despite having proprietary manufacturing capabilities, are known to outsource more than half of their clinical stage oligonucleotide manufacturing operations. In the foreseen future, we anticipate the demand and opportunities for contract manufacturing organizations (CMO) in this domain to rise. Consequently, CMOs need to continue to upgrade their capabilities and infrastructure to keep pace with the evolving product development landscape.

Scope of the Report:

The “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030” report features a detailed study of the current scenario and future potential of the custom synthesis, modification and purification services market for oligonucleotides, which are intended for research, diagnostic, and therapeutic applications.

Table of Contents

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Overview of Oligonucleotide-based Products
  • 3.3. Types of Oligonucleotides
    • 3.3.1. Antisense Oligonucleotides
    • 3.3.2. Aptamers
    • 3.3.3. miRNA
    • 3.3.4. shRNA
    • 3.3.5. siRNA
    • 3.3.6. Other Oligonucleotides
  • 3.4. Custom Synthesis of Oligonucleotides
    • 3.4.1. Process Development and Characterization
    • 3.4.2. Analytical Method Development
    • 3.4.3. Method Validation and Testing
    • 3.4.4. Quality Control and Quality Assurance
    • 3.4.5. Challenges Associated with Custom Synthesis of Oligonucleotides
  • 3.5. Chemical Modification of Oligonucleotides
    • 3.5.1. Backbone Modification
    • 3.5.2. Sugar Ring Modification
  • 3.6. Purification of Oligonucleotides
    • 3.6.1. Desalting
    • 3.6.2. Cartridge Purification
    • 3.6.3. Polyacrylamide Gel Electrophoresis (PAGE)
    • 3.6.4. High Performance Liquid Chromatography (HPLC)
  • 3.7. Outsourcing Oligonucleotide Manufacturing
    • 3.7.1. Need for Outsourcing
    • 3.7.2. Commonly Outsourced Operations
    • 3.7.3. Advantages of Outsourcing Manufacturing Operations
    • 3.7.4. Guidelines for Selecting a Service Provider
  • 3.8. Growth Drivers and Roadblocks to Oligonucleotide Manufacturing
  • 3.9. Recent Developments and Upcoming Trends

4. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS)

  • 4.1. Chapter Overview
  • 4.2. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Application
    • 4.2.4. Analysis by Scale of Operation
    • 4.2.5. Analysis by Geographical Location
    • 4.2.6. Analysis by Location of Manufacturing Facilities
    • 4.2.7. Analysis by Regulatory Accreditations / Certifications
    • 4.2.8. Analysis by Type of Oligonucleotide Manufactured
    • 4.2.9. Analysis by Type of Offering
    • 4.2.10. Analysis by Type of Manufacturing Service(s) Offered
    • 4.2.11. Analysis by Type of Modification(s) Offered
    • 4.2.12. Analysis by Type of Purification Method(s) Used
    • 4.2.13. Analysis by Compliance to cGMP Standards

5. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)

  • 5.1. Chapter Overview
  • 5.2. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Overall Market Landscape
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Scale of Operation
    • 5.2.4. Analysis by Geographical Location
    • 5.2.5. Analysis by Location of Manufacturing Facilities
    • 5.2.6. Analysis by Regulatory Accreditations / Certifications
    • 5.2.7. Analysis by Type of Oligonucleotide Manufactured
    • 5.2.8. Analysis by Type of Offering
    • 5.2.9. Analysis by Type of Manufacturing Service(s) Offered
    • 5.2.10. Analysis by Type of Modification(s) Offered
    • 5.2.11. Analysis by Type of Purification Method(s) Used
    • 5.2.12. Analysis by Compliance to cGMP Standards

6. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURES (RESEARCH AND DIAGNOSTIC APPLICATIONS)

  • 6.1. Chapter Overview
  • 6.2. Key Assumptions and Methodology
  • 6.3. Company Competitiveness Analysis: Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications
    • 6.3.1. Oligonucleotide Manufacturers in North America
    • 6.3.2. Oligonucleotide Manufacturers in Europe
    • 6.3.3. Oligonucleotide Manufacturers in Asia-Pacific

7. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)

  • 7.1. Chapter Overview
  • 7.2. Key Assumptions and Methodology
  • 7.3. Company Competitiveness Analysis: Oligonucleotide Manufacturers Focused on Therapeutic Applications
    • 7.3.1. Oligonucleotide Manufacturers in North America
    • 7.3.2. Oligonucleotide Manufacturers in Europe
    • 7.3.3. Oligonucleotide Manufacturers in Asia-Pacific

8. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (RESEARCH AND DIAGNOSTIC APPLICATIONS)

  • 8.1. Chapter Overview
  • 8.2. Ajinomoto Bio-Pharma Services
    • 8.2.1. Company Overview
    • 8.2.2. Service Portfolio
    • 8.2.3. Manufacturing Facilities and Capabilities
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Integrated DNA Technologies
    • 8.3.1. Company Overview
    • 8.3.2. Service Portfolio
    • 8.3.3. Manufacturing Facilities and Capabilities
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. Kaneka Eurogentec
    • 8.4.1. Company Overview
    • 8.4.2. Service Portfolio
    • 8.4.3. Manufacturing Facilities and Capabilities
    • 8.4.4. Recent Developments and Future Outlook
  • 8.5. LGC Biosearch Technologies
    • 8.5.1. Company Overview
    • 8.5.2. Service Portfolio
    • 8.5.3. Manufacturing Facilities and Capabilities
    • 8.5.4. Recent Developments and Future Outlook
  • 8.6. Microsynth
    • 8.6.1. Company Overview
    • 8.6.2. Service Portfolio
    • 8.6.3. Manufacturing Facilities and Capabilities
    • 8.6.4. Recent Developments and Future Outlook
  • 8.7. Sigma Aldrich
    • 8.7.1. Company Overview
    • 8.7.2. Financial Information
    • 8.7.3. Service Portfolio
    • 8.7.4. Manufacturing Facilities and Capabilities
    • 8.7.5. Recent Developments and Future Outlook
  • 8.8. Thermo Fisher Scientific
    • 8.8.1. Company Overview
    • 8.8.2. Financial Information
    • 8.8.3. Service Portfolio
    • 8.8.4. Manufacturing Facilities and Capabilities
    • 8.8.5. Recent Developments and Future Outlook

9. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)

  • 9.1. Chapter Overview
  • 9.2. Agilent Technologies
    • 9.2.1. Company Overview
    • 9.2.2. Financial Information
    • 9.2.3. Service Portfolio
    • 9.2.4. Manufacturing Facilities and Capabilities
    • 9.2.5. Recent Developments and Future Outlook
  • 9.3. BioSpring
    • 9.3.1. Company Overview
    • 9.3.2. Service Portfolio
    • 9.3.3. Manufacturing Facilities and Capabilities
    • 9.3.4. Recent Developments and Future Outlook
  • 9.4. CordenPharma
    • 9.4.1. Company Overview
    • 9.4.2. Service Portfolio
    • 9.4.3. Manufacturing Facilities and Capabilities
    • 9.4.4. Recent Developments and Future Outlook
  • 9.5. Nitto Denko Avecia
    • 9.5.1. Company Overview
    • 9.5.2. Service Portfolio
    • 9.5.3. Manufacturing Facilities and Capabilities
    • 9.5.4. Recent Developments and Future Outlook
  • 9.6. TriLink Biotechnologies
    • 9.6.1. Company Overview
    • 9.6.2. Service Portfolio
    • 9.6.3. Manufacturing Facilities and Capabilities
    • 9.6.4. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Oligonucleotide Manufacturers: Recent Partnerships and Collaborations
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Type of Partner
    • 10.3.4. Most Active Players: Analysis by Number of Partnerships
    • 10.3.5. Geographical Analysis
      • 10.3.5.1. Most Active Players: Geographical Distribution by Number of Partnerships
      • 10.3.5.2. Intercontinental and Intracontinental Agreements

11. RECENT EXPANSIONS

  • 11.1. Chapter Overview
  • 11.2. Oligonucleotide Manufacturers: Recent Expansions
    • 11.2.1. Analysis by Year of Expansion
    • 11.2.2. Analysis by Type of Expansion
    • 11.2.3. Analysis by Application
    • 11.2.4. Analysis by Location of Facility
    • 11.2.5. Analysis by Expanded Facility Area
    • 11.2.6. Analysis by Expanded Scale of Operation
    • 11.3.7. Most Active Players: Analysis by Number of Expansions
    • 11.3.8. Geographical Analysis
      • 11.3.8.1. Continent-wise Distribution
      • 11.3.8.2. Country-wise Distribution

12. CLINICAL TRIAL ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Clinical Trial Analysis: Oligonucleotide-based Drug Products
    • 12.3.1. Analysis by Trial Registration Year
    • 12.3.2. Analysis by Phase of Development
    • 12.3.3. Analysis by Type of Oligonucleotide
    • 12.3.4. Analysis by Trial Recruitment Status
    • 12.3.5. Analysis by Trial Focus Area
    • 12.3.6. Analysis by Target Therapeutic Area
    • 12.3.7. Geographical Analysis by Number of Clinical Trials
    • 12.3.8. Geographical Analysis by Enrolled Patient Population
    • 12.3.9. Analysis by Type of Sponsor / Collaborator
    • 12.3.10. Most Active Players: Analysis by Number of Registered Trials
    • 12.3.11. Competitive Benchmarking (Clinical Research): Active Industry Player

13. CAPACITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. Oligonucleotide Manufacturers: Global, Installed Capacity
    • 13.3.1. Analysis by Company Size
    • 13.3.2. Analysis by Scale of Operation
    • 13.3.3. Analysis by Location of Manufacturing Facility
  • 13.4. Concluding Remarks

14. DEMAND ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Global Commercial Demand for Oligonucleotide Manufacturing
    • 14.3.1. Analysis by Target Therapeutic Area
    • 14.3.2. Analysis by Scale of Operation
    • 14.3.3. Analysis by Geography
  • 14.4. Global Clinical Demand for Oligonucleotide Manufacturing
    • 14.4.1. Analysis by Target Therapeutic Area
    • 14.4.2. Analysis by Scale of Operation
    • 14.4.3. Analysis by Geography
  • 14.5. Demand and Supply Analysis

15. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Forecast Methodology
  • 15.3. Overall Oligonucleotide Manufacturing Market, 2020-2030
  • 15.4. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Application
    • 15.4.1. Oligonucleotide Manufacturing Market Focused on Research and Diagnostic Applications, 2020-2030
    • 15.4.2. Oligonucleotide Manufacturing Market Focused on Therapeutic Applications, 2020-2030
  • 15.5. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Type of Oligonucleotide Manufactured
    • 15.5.1. Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2020-2030
    • 15.5.2. Oligonucleotide Manufacturing Market for siRNA, 2020-2030
    • 15.5.3. Oligonucleotide Manufacturing Market for miRNA, 2020-2030
    • 15.5.4. Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2020-2030
  • 15.6. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Scale of Operation
    • 15.6.1. Oligonucleotide Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030
    • 15.6.2. Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2020-2030
  • 15.7. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Company Size
    • 15.7.1. Oligonucleotide Manufacturing Market for Small Companies, 2020-2030
    • 15.7.2. Oligonucleotide Manufacturing Market for Mid-sized Companies, 2020-2030
    • 15.7.3. Oligonucleotide Manufacturing Market for Large Companies, 2020-2030
  • 15.8. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Target Therapeutic Area
    • 15.8.1. Oligonucleotide Manufacturing Market for Oncological Disorders, 2020-2030
    • 15.8.2. Oligonucleotide Manufacturing Market for Eye Disorders, 2020-2030
    • 15.8.3. Oligonucleotide Manufacturing Market for Metabolic Disorders, 2020-2030
    • 15.8.4. Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2020-2030
    • 15.8.5. Oligonucleotide Manufacturing Market for Other Therapeutic Areas, 2020-2030
  • 15.9. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Geography
    • 15.9.1. Oligonucleotide Manufacturing Market in North America, 2020-2030
    • 15.9.2. Oligonucleotide Manufacturing Market in Europe, 2020-2030
    • 15.9.3. Oligonucleotide Manufacturing Market in Asia-Pacific, 2020-2030
    • 15.9.4. Oligonucleotide Manufacturing Market in Rest of the World, 2020-2030

16. SWOT ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Comparison of SWOT Factors

17. SURVEY ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Overview of Respondents
    • 17.2.1. Seniority Level of Respondents
  • 17.3. Survey Insights
    • 17.3.1. Type of Offering
    • 17.3.2. Application
    • 17.3.3. Manufacturing Capacity
    • 17.3.4. Location of Manufacturing Facilities
    • 17.3.5. Extent of Outsourcing
    • 17.3.6. Current Market Opportunity

18. EXECUTIVE INSIGHTS

  • 18.1. Chapter Overview
  • 18.2. BianoScience
    • 18.2.1. Company Snapshot
    • 18.2.2. Interview Transcript: Tobias Pohlmann, Founder and Managing Director
  • 18.3. IBA Life Sciences
    • 18.3.1. Company Snapshot
    • 18.3.2. Interview Transcript: Joachim Bertram, Chief Scientific Officer and Managing Director

19. CONCLUDING REMARKS

  • 19.1. Chapter Overview
  • 19.2. Key Takeaways

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Classification of Oligonucleotides
  • Figure 3.2 Steps Involved in the Manufacturing of Oligonucleotides
  • Figure 3.3 Types of Chemical Modifications of Oligonucleotides
  • Figure 3.4 Types of Purification Methods Used for Oligonucleotides
  • Figure 3.5 Types of Standalone Service Providers
  • Figure 3.6 Services Offered by Oligonucleotide Manufacturers
  • Figure 3.7 Commonly Outsourced Operations
  • Figure 3.8 Guidelines for Selecting a Service Provider
  • Figure 3.9 Growth Drivers and Roadblocks to Oligonucleotide Manufacturing
  • Figure 4.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
  • Figure 4.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
  • Figure 4.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Application
  • Figure 4.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
  • Figure 4.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment, Company Size and Scale of Operation
  • Figure 4.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)
  • Figure 4.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
  • Figure 4.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
  • Figure 4.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
  • Figure 4.12 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
  • Figure 4.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
  • Figure 4.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Modification(s) Offered
  • Figure 4.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method(s) Used
  • Figure 4.16 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Compliance to cGMP Standards
  • Figure 5.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
  • Figure 5.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
  • Figure 5.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
  • Figure 5.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment, Company Size and Scale of Operation
  • Figure 5.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Region-wise)
  • Figure 5.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Country-wise)
  • Figure 5.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)
  • Figure 5.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
  • Figure 5.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
  • Figure 5.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
  • Figure 5.11 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
  • Figure 5.12 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service(s) Offered
  • Figure 5.13 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Modification(s) Offered
  • Figure 5.14 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method(s) Used
  • Figure 5.15 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Compliance to cGMP Standards
  • Figure 6.1 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in North America
  • Figure 6.2 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in Europe
  • Figure 6.3 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in Asia-Pacific
  • Figure 7.1 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Therapeutic Applications in North America
  • Figure 7.2 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Therapeutic Applications in Europe
  • Figure 7.3 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Therapeutic Applications in Asia-Pacific
  • Figure 8.1 Sigma Aldrich: Net Revenues, FY 2015 - H1 FY 2019 (USD Million)
  • Figure 8.2 Sigma Aldrich: Distribution of Net Revenues by Business Segment, FY 2018 (USD Million)
  • Figure 8.3 Thermo Fisher Scientific: Net Revenues, FY 2014 - FY 2019 (USD Billion)
  • Figure 8.4 Thermo Fisher Scientific: Distribution of Net Revenues by Business Segment, FY 2019 (USD Billion)
  • Figure 9.1 Agilent Technologies: Net Revenues, FY 2015 - FY 2018 (USD Billion)
  • Figure 9.2 Agilent Technologies: Distribution of Net Revenues by Business Segment, FY 2018 (USD Billion)
  • Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership, 2014-2019
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2014-2019
  • Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 10.5 Most Active Players: Distribution by Number of Partnerships
  • Figure 10.6 Most Active Players: Geographical Distribution by Number of Partnerships
  • Figure 10.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 11.1 Recent Expansions: Distribution by Year of Expansion, 2014-2019
  • Figure 11.2 Recent Expansions: Distribution by Type of Expansion
  • Figure 11.3 Recent Expansions: Year-wise Trend by Type of Expansion, 2014-2019
  • Figure 11.4 Recent Expansions: Distribution by Application
  • Figure 11.5 Recent Expansions: Distribution by Location of Facility
  • Figure 11.6 Recent Expansions: Distribution by Type of Expansion and Location of Facility
  • Figure 11.7 Recent Expansions: Distribution by Type of Expansion and Application
  • Figure 11.8 Recent Expansions: Distribution by Expanded Facility Area (sq ft)
  • Figure 11.9 Recent Expansions: Distribution by Expanded Scale of Operation
  • Figure 11.10 Most Active Players: Distribution by Number of Expansions
  • Figure 11.11 Recent Expansions: Distribution by Geography
  • Figure 11.12 Recent Expansions: Year-wise Trend by Geography, 2014-2019
  • Figure 12.1 Clinical Trials: Distribution by Trial Registration Year, Pre-2012-2019
  • Figure 12.2 Clinical Trials: Distribution by Phase of Development
  • Figure 12.3 Clinical Trials: Distribution by Type of Oligonucleotide
  • Figure 12.4 Clinical Trials: Distribution by Trial Registration Year and Type of Oligonucleotide, Pre-2012-2019
  • Figure 12.5 Clinical Trials: Distribution by Trial Recruitment Status
  • Figure 12.6 Clinical Trials: Distribution by Trial Registration Year and Recruitment Status, Pre-2012-2019
  • Figure 12.7 Clinical Trials: Popular Keywords
  • Figure 12.8 Clinical Trials: Distribution by Target Therapeutic Area
  • Figure 12.9 Clinical Trials: Distribution by Trial Registration Year and Target Therapeutic Area, Pre-2012-2019
  • Figure 12.10 Clinical Trials: Geographical Distribution by Number of Clinical Trials
  • Figure 12.11 Clinical Trials: Geographical Distribution by Trial Registration Year, Pre-2012-2019
  • Figure 12.12 Clinical Trials: Geographical Distribution by Enrolled Patient Population
  • Figure 12.13 Clinical Trials: Cumulative Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2012-2019
  • Figure 12.14 Clinical Trials: Distribution by Type of Sponsor / Collaborator
  • Figure 12.15 Clinical Trials: Distribution by Type of Sponsor / Collaborator and Target Therapeutic Area
  • Figure 12.16 Most Active Industry Players: Distribution by Number of Registered Trials
  • Figure 12.17 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 12.18 Clinical Trials: Distribution by Trial Registration Year and Most Active Industry Players, 2014-2019
  • Figure 12.19 Clinical Trials: Benchmarking by Number of Trials across Key Therapeutic Areas
  • Figure 13.1 Global Oligonucleotide Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
  • Figure 13.2 Global Oligonucleotide Manufacturing Capacity: Distribution by Company Size (Grams)
  • Figure 13.3 Global Oligonucleotide Manufacturing Capacity: Distribution by Scale of Operation (Grams)
  • Figure 13.4 Global Oligonucleotide Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Grams)
  • Figure 14.1 Global, Commercial Demand for Oligonucleotide Manufacturing (Grams)
  • Figure 14.2 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Grams)
  • Figure 14.3 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Scale of Operation (Grams)
  • Figure 14.4 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Geography (Grams)
  • Figure 14.5 Global, Clinical Demand for Oligonucleotide Manufacturing (Grams)
  • Figure 14.6 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Grams)
  • Figure 14.7 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Scale of Operation (Grams)
  • Figure 14.8 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Geography (Grams)
  • Figure 14.8 Global Oligonucleotide Manufacturing: Demand and Supply
  • Figure 15.1 Overall Oligonucleotide Manufacturing Market, 2020-2030 (USD Million)
  • Figure 15.2 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Application (USD Million)
  • Figure 15.3 Oligonucleotide Manufacturing Market Focused on Research and Diagnostic Applications, 2020-2030 (USD Million)
  • Figure 15.4 Oligonucleotide Manufacturing Market Focused on Therapeutic Applications, 2020-2030 (USD Million)
  • Figure 15.5 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Type of Oligonucleotide Manufactured (USD Million)
  • Figure 15.6 Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2020-2030 (USD Million)
  • Figure 15.7 Oligonucleotide Manufacturing Market for siRNA, 2020-2030 (USD Million)
  • Figure 15.8 Oligonucleotide Manufacturing Market for miRNA, 2020-2030 (USD Million)
  • Figure 15.9 Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2020-2030 (USD Million)
  • Figure 15.10 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Million)
  • Figure 15.11 Oligonucleotide Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
  • Figure 15.12 Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2020-2030 (USD Million)
  • Figure 15.13 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Company Size (USD Million)
  • Figure 15.14 Oligonucleotide Manufacturing Market for Small Companies, 2020-2030 (USD Million)
  • Figure 15.15 Oligonucleotide Manufacturing Market for Mid-sized Companies, 2020-2030 (USD Million)
  • Figure 15.16 Oligonucleotide Manufacturing Market for Large Companies, 2020-2030 (USD Million)
  • Figure 15.17 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area (USD Million)
  • Figure 15.18 Oligonucleotide Manufacturing Market for Oncological Disorders, 2020-2030 (USD Million)
  • Figure 15.19 Oligonucleotide Manufacturing Market for Eye Disorders, 2020-2030 (USD Million)
  • Figure 15.20 Oligonucleotide Manufacturing Market for Metabolic Disorders, 2020-2030 (USD Million)
  • Figure 15.21 Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2020-2030 (USD Million)
  • Figure 15.22 Oligonucleotide Manufacturing Market for Other Therapeutic Areas, 2020-2030 (USD Million)
  • Figure 15.23 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Geography (USD Million)
  • Figure 15.24 Oligonucleotide Manufacturing Market in North America, 2020-2030 (USD Million)
  • Figure 15.25 Oligonucleotide Manufacturing Market in Europe, 2020-2030 (USD Million)
  • Figure 15.26 Oligonucleotide Manufacturing Market in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 15.27 Oligonucleotide Manufacturing Market in Rest of the World, 2020-2030 (USD Million)
  • Figure 16.1 Oligonucleotide Manufacturing Market: SWOT Analysis
  • Figure 16.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 17.1 Survey Insights: Distribution by Type of Organization
  • Figure 17.2 Survey Insights: Distribution by Location of Organization
  • Figure 17.3 Survey Insights: Distribution by Seniority Level
  • Figure 17.4 Survey Insights: Distribution by Type of Offering
  • Figure 17.5 Survey Insights: Distribution by Application
  • Figure 17.6 Survey Insights: Distribution by Location of Manufacturing Facilities
  • Figure 17.7 Survey Insights: Distribution by Extent of Outsourcing
  • Figure 17.8 Survey Insights: Distribution by Current Market Opportunity

List Of Tables

  • Table 4.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players
  • Table 4.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
  • Table 4.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
  • Table 4.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Manufacturing Service(s) Offered
  • Table 4.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Modification(s) Offered, Type of Purification Method(s) Used and Compliance to cGMP Standards
  • Table 5.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players
  • Table 5.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
  • Table 5.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
  • Table 5.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Manufacturing Service(s) Offered
  • Table 5.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Modification(s) Offered, Type of Purification Method(s) Used and Compliance to cGMP Standards
  • Table 8.1 Ajinomoto Bio-Pharma Services: Key Highlights
  • Table 8.2 Ajinomoto Bio-Pharma Services: Service Portfolio
  • Table 8.3 Ajinomoto Bio-Pharma Services: Manufacturing Facilities and Capabilities
  • Table 8.4 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
  • Table 8.5 Integrated DNA Technologies: Key Highlights
  • Table 8.6 Integrated DNA Technologies: Service Portfolio
  • Table 8.7 Integrated DNA Technologies: Manufacturing Facilities and Capabilities
  • Table 8.8 Integrated DNA Technologies: Recent Developments and Future Outlook
  • Table 8.9 Kaneka Eurogentec: Key Highlights
  • Table 8.10 Kaneka Eurogentec: Service Portfolio
  • Table 8.11 Kaneka Eurogentec: Manufacturing Facilities and Capabilities
  • Table 8.12 Kaneka Eurogentec: Recent Developments and Future Outlook
  • Table 8.13 LGC, Biosearch Technologies: Key Highlights
  • Table 8.14 LGC, Biosearch Technologies: Service Portfolio
  • Table 8.15 LGC, Biosearch Technologies: Manufacturing Facilities and Capabilities
  • Table 8.16 LGC, Biosearch Technologies: Recent Developments and Future Outlook
  • Table 8.17 Microsynth: Key Highlights
  • Table 8.18 Microsynth: Service Portfolio
  • Table 8.19 Microsynth: Manufacturing Facilities and Capabilities
  • Table 8.20 Microsynth: Recent Developments and Future Outlook
  • Table 8.21 Sigma Aldrich: Key Highlights
  • Table 8.22 Sigma Aldrich: Service Portfolio
  • Table 8.23 Sigma Aldrich: Manufacturing Facilities and Capabilities
  • Table 8.24 Sigma Aldrich: Recent Developments and Future Outlook
  • Table 8.25 Thermo Fisher Scientific: Key Highlights
  • Table 8.26 Thermo Fisher Scientific: Service Portfolio
  • Table 8.27 Thermo Fisher Scientific: Manufacturing Facilities and Capabilities
  • Table 8.28 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 9.1 Agilent Technologies: Key Highlights
  • Table 9.2 Agilent Technologies: Service Portfolio
  • Table 9.3 Agilent Technologies: Manufacturing Facilities and Capabilities
  • Table 9.4 Agilent Technologies: Recent Developments and Future Outlook
  • Table 9.5 BioSpring: Key Highlights
  • Table 9.6 BioSpring: Service Portfolio
  • Table 9.7 BioSpring: Manufacturing Facilities and Capabilities
  • Table 9.8 BioSpring: Recent Developments and Future Outlook
  • Table 9.9 CordenPharma: Key Highlights
  • Table 9.10 CordenPharma: Service Portfolio
  • Table 9.11 CordenPharma: Manufacturing Facilities and Capabilities
  • Table 9.12 CordenPharma: Recent Developments and Future Outlook
  • Table 9.13 Nitto Denko Avecia: Key Highlights
  • Table 9.14 Nitto Denko Avecia: Service Portfolio
  • Table 9.15 Nitto Denko Avecia: Manufacturing Facilities and Capabilities
  • Table 9.16 Nitto Denko Avecia: Recent Developments and Future Outlook
  • Table 9.17 TriLink Biotechnologies: Key Highlights
  • Table 9.18 TriLink Biotechnologies: Service Portfolio
  • Table 9.19 TriLink Biotechnologies: Manufacturing Facilities and Capabilities
  • Table 9.20 TriLink Biotechnologies: Recent Developments and Future Outlook
  • Table 10.1 Oligonucleotide Manufacturers: List of Partnerships, 2014-2019
  • Table 10.2 Most Active Players: Geographical Distribution by Type of Partnership Model
  • Table 11.1 Oligonucleotide Manufacturers: List of Expansions, 2014-2019
  • Table 13.1 Global Oligonucleotide Manufacturing Capacity: Average Capacity based on Company Size (Sample Data Set)
  • Table 13.2 Global Oligonucleotide Manufacturing Capacity: Average Capacity based on Scale of Operation (Sample Data Set)
  • Table 13.3 Global Oligonucleotide Manufacturing Capacity: Average Capacity based on Location of Company (Sample Data Set)
  • Table 17.1 Survey Insights: Overview of Respondents
  • Table 17.2 Survey Insights: Seniority Level of Respondents
  • Table 17.3 Survey Insights: Type of Offering
  • Table 17.4 Survey Insights: Application
  • Table 17.5 Survey Insights: Oligonucleotide Manufacturing Capacity
  • Table 17.6 Survey Insights: Number and Location of Manufacturing Facilities
  • Table 17.7 Survey Insights: Extent of Outsourcing
  • Table 17.8 Survey Insights: Current Market Opportunity (USD Million)
  • Table 18.1 BianoScience: Key Highlights
  • Table 18.2 IBA Life Sciences: Key Highlights
  • Table 19.1 Oligonucleotide Manufacturing Market: Key Takeaways
  • Table 20.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
  • Table 20.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
  • Table 20.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Application
  • Table 20.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
  • Table 20.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Region-wise)
  • Table 20.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Country-wise)
  • Table 20.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)
  • Table 20.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
  • Table 20.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
  • Table 20.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
  • Table 20.12 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
  • Table 20.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
  • Table 20.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Modification(s) Offered
  • Table 20.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method(s) Used
  • Table 20.16 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Compliance to cGMP Standards
  • Table 20.17 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
  • Table 20.18 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
  • Table 20.19 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
  • Table 20.20 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Region-wise)
  • Table 20.21 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Country-wise)
  • Table 20.22 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)
  • Table 20.23 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
  • Table 20.24 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
  • Table 20.25 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
  • Table 20.26 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
  • Table 20.27 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service(s) Offered
  • Table 20.28 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Modification(s) Offered
  • Table 20.29 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method(s) Used
  • Table 20.30 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Compliance to cGMP Standards
  • Table 20.31 Sigma Aldrich: Net Revenues, FY 2015 - H1 FY 2019 (USD Million)
  • Table 20.32 Sigma Aldrich: Distribution of Net Revenues by Business Segment, FY 2018 (USD Million)
  • Table 20.33 Thermo Fisher Scientific: Net Revenues, FY 2014 - FY 2019 (USD Billion)
  • Table 20.34 Thermo Fisher Scientific: Distribution of Net Revenues by Business Segment, FY 2019 (USD Billion)
  • Table 20.35 Agilent Technologies: Net Revenues, FY 2015 - FY 2018 (USD Billion)
  • Table 20.36 Agilent Technologies: Distribution of Net Revenues by Business Segment, FY 2018 (USD Billion)
  • Table 20.37 Partnerships and Collaborations: Distribution by Year of Partnership, 2014-2019
  • Table 20.38 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 20.39 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2014-2019
  • Table 20.40 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 20.41 Most Active Players: Distribution by Number of Partnerships
  • Table 20.42 Most Active Players: Geographical Distribution by Number of Partnerships
  • Table 20.43 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 20.44 Recent Expansions: Distribution by Year of Expansion, 2014-2019
  • Table 20.45 Recent Expansions: Distribution by Type of Expansion
  • Table 20.46 Recent Expansions: Year-wise Trend by Type of Expansion, 2014-2019
  • Table 20.47 Recent Expansions: Distribution by Application
  • Table 20.48 Recent Expansions: Distribution by Location of Facility
  • Table 20.49 Recent Expansions: Distribution by Type of Expansion and Location of Facility
  • Table 20.50 Recent Expansions: Distribution by Type of Expansion and Application
  • Table 20.51 Recent Expansions: Distribution by Expanded Facility Area (sq ft)
  • Table 20.52 Recent Expansions: Distribution by Expanded Scale of Operation
  • Table 20.53 Most Active Players: Distribution by Number of Expansions
  • Table 20.54 Recent Expansions: Distribution by Geography
  • Table 20.55 Recent Expansions: Year-wise Trend by Geography, 2014-2019
  • Table 20.56 Clinical Trials: Distribution by Trial Registration Year, Pre-2012-2019
  • Table 20.57 Clinical Trials: Distribution by Phase of Development
  • Table 20.58 Clinical Trials: Distribution by Type of Oligonucleotide
  • Table 20.59 Clinical Trials: Distribution by Trial Registration Year and Type of Oligonucleotide, Pre-2012-2019
  • Table 20.60 Clinical Trials: Distribution by Trial Recruitment Status
  • Table 20.61 Clinical Trials: Distribution by Trial Registration Year and Recruitment Status, Pre-2012-2019
  • Table 20.62 Clinical Trials: Distribution by Target Therapeutic Area
  • Table 20.63 Clinical Trials: Distribution by Trial Registration Year and Target Therapeutic Area, Pre-2012-2019
  • Table 20.64 Clinical Trials: Geographical Distribution by Number of Clinical Trials
  • Table 20.65 Clinical Trials: Geographical Distribution by Trial Registration Year, Pre-2012-2019
  • Table 20.66 Clinical Trials: Geographical Distribution by Enrolled Patient Population
  • Table 20.67 Clinical Trials: Cumulative Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2012-2019
  • Table 20.68 Clinical Trials: Distribution by Type of Sponsor / Collaborator
  • Table 20.69 Clinical Trials: Distribution by Type of Sponsor / Collaborator and Target Therapeutic Area
  • Table 20.70 Most Active Industry Players: Distribution by Number of Registered Trials
  • Table 20.71 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Table 20.72 Clinical Trials: Distribution by Trial Registration Year and Most Active Industry Players, 2014-2019
  • Table 20.73 Clinical Trials: Benchmarking by Number of Trials across Key Therapeutic Areas
  • Table 20.74 Global Oligonucleotide Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
  • Table 20.75 Global Oligonucleotide Manufacturing Capacity: Distribution by Company Size (Grams)
  • Table 20.76 Global Oligonucleotide Manufacturing Capacity: Distribution by Scale of Operation (Grams)
  • Table 20.77 Global Oligonucleotide Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Grams)
  • Table 20.78 Global, Commercial Demand for Oligonucleotide Manufacturing (Grams)
  • Table 20.79 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Grams)
  • Table 20.80 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Scale of Operation (Grams)
  • Table 20.81 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Geography (Grams)
  • Table 20.82 Global, Clinical Demand for Oligonucleotide Manufacturing (Grams)
  • Table 20.83 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Grams)
  • Table 20.84 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Scale of Operation (Grams)
  • Table 20.85 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Geography (Grams)
  • Table 20.86 Global Oligonucleotide Manufacturing: Demand and Supply
  • Table 20.87 Overall Oligonucleotide Manufacturing Market, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.88 Oligonucleotide Manufacturing Market: Distribution by Application, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.89 Oligonucleotide Manufacturing Market Focused on Research and Diagnostic Applications, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.90 Oligonucleotide Manufacturing Market Focused on Therapeutic Applications, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.91 Oligonucleotide Manufacturing Market: Distribution by Type of Oligonucleotide Manufactured, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.92 Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.93 Oligonucleotide Manufacturing Market for siRNA, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.94 Oligonucleotide Manufacturing Market for miRNA, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.95 Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.96 Oligonucleotide Manufacturing Market: Distribution by Scale of Operation, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.97 Oligonucleotide Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.98 Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.99 Oligonucleotide Manufacturing Market: Distribution by Company Size, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.100 Oligonucleotide Manufacturing Market for Small Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.101 Oligonucleotide Manufacturing Market for Mid-sized Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.102 Oligonucleotide Manufacturing Market for Large Companies, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.103 Oligonucleotide Manufacturing Market: Distribution by Target Therapeutic Area, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.104 Oligonucleotide Manufacturing Market for Oncological Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.105 Oligonucleotide Manufacturing Market for Eye Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.106 Oligonucleotide Manufacturing Market for Metabolic Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.107 Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.108 Oligonucleotide Manufacturing Market for Other Therapeutic Areas, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.109 Oligonucleotide Manufacturing Market: Distribution by Geography, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.110 Oligonucleotide Manufacturing Market in North America, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.111 Oligonucleotide Manufacturing Market in Europe, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.112 Oligonucleotide Manufacturing Market in Asia-Pacific, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.113 Oligonucleotide Manufacturing Market in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 20.114 Survey Insights: Distribution by Type of Organization
  • Table 20.115 Survey Insights: Distribution by Location of Organization
  • Table 20.116 Survey Insights: Distribution by Seniority Level
  • Table 20.117 Survey Insights: Distribution by Type of Offering
  • Table 20.117 Survey Insights: Distribution by Application
  • Table 20.118 Survey Insights: Distribution by Location of Manufacturing Facilities
  • Table 20.119 Survey Insights: Distribution by Extent of Outsourcing
  • Table 20.120 Survey Insights: Distribution by Current Market Opportunity

Listed Companies

The following companies and organizations have been mentioned in the report:

  • 1. A/Z
  • 2. Aarhus University
  • 3. Abacus dx
  • 4. Abbott
  • 5. AbbVie
  • 6. ACGT
  • 7. Achieve Life Sciences
  • 8. Aegera Therapeutics
  • 9. Aeras
  • 10. Agilent Technologies
  • 11. AITbiotech
  • 12. Ajinomoto Bio-Pharma Services
  • 13. Akcea Therapeutics
  • 14. Allele Biotechnology & Pharmaceuticals
  • 15. Allergan
  • 16. Allianz BioInnovation
  • 17. Alnylam Pharmaceuticals
  • 18. Alta Bioscience
  • 19. AM Chemicals
  • 20. Amgen
  • 21. AmpTec
  • 22. Anesiva
  • 23. AnGes
  • 24. Applied Biological Materials
  • 25. Aptose Biosciences
  • 26. Arbutus Biopharma
  • 27. Archemix
  • 28. Argonaut Manufacturing Services
  • 29. Arrowhead Pharmaceuticals
  • 30. AstraZeneca
  • 31. ATDBio
  • 32. ATZ Labs
  • 33. Averica Discovery Services
  • 34. Avrio Biopharmaceuticals
  • 35. Axolabs
  • 36. Bachem
  • 37. Band Therapeutics
  • 38. Baylor College of Medicine
  • 39. Benitec Biopharma
  • 40. Berry & Associates
  • 41. BianoScience
  • 42. Bio Basic
  • 43. BioAutomation
  • 44. Biolegio
  • 45. BioLineRx
  • 46. Bioneer
  • 47. Bio-Path Holdings
  • 48. Biosearch Technologies
  • 49. BioServe Biotechnologies
  • 50. BioSpring
  • 51. Bio-Synthesis
  • 52. Boston Children's Hospital
  • 53. BR Biochem Life Sciences
  • 54. Bridgen
  • 55. Brigham and Women's Hospital
  • 56. Bristol-Myers Squibb
  • 57. British Columbia Cancer Agency
  • 58. bts Biotech Trade & Service
  • 59. Calimmune
  • 60. Canadian Cancer Trials Group
  • 61. Cancer Genetics
  • 62. Celgene
  • 63. Central Finland Central Hospital
  • 64. ChemGenes
  • 65. Co-Diagnostics
  • 66. CordenPharma
  • 67. Creative Biogene
  • 68. CSL Behring
  • 69. CUSABIO TECHNOLOGY
  • 70. CyberGene
  • 71. Daiichi Sankyo
  • 72. Dalton Pharma Services
  • 73. Dana-Farber Cancer Institute
  • 74. Dharmacon
  • 75. Dicerna Pharmaceuticals
  • 76. Dizal Pharmaceutical
  • 77. Duke University
  • 78. Dynacure
  • 79. Dynavax Technologies
  • 80. Eastern Cooperative Oncology Group
  • 81. Elim Biopharmaceuticals
  • 82. EMD Serono
  • 83. Enzon Pharmaceuticals
  • 84. Eton Bioscience
  • 85. Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • 86. Eurofins Genomics
  • 87. European Organisation for Research and Treatment of Cancer
  • 88. Expedeon
  • 89. Eyetech Pharmaceuticals
  • 90. FGK Clinical Research
  • 91. Fred Hutchinson Cancer Research Center
  • 92. FUTUREsynthesis
  • 93. GCC Biotech
  • 94. GE Healthcare
  • 95. Genbiotech
  • 96. Gene Universal
  • 97. GeneDesign
  • 98. Genei Laboratories
  • 99. GenePharma
  • 100. General Biosystems
  • 101. GENERI BIOTECH
  • 102. GENEWIZ
  • 103. GeneWorks
  • 104. GenScript
  • 105. Genta
  • 106. Genzyme
  • 107. George Washington University
  • 108. Georgetown University
  • 109. German CLL Study Group
  • 110. German Federal Ministry of Education and Research
  • 111. Gradalis
  • 112. Granzer Regulatory Consulting & Services
  • 113. Hanugen Therapeutics
  • 114. Helsinki University Central Hospital
  • 115. HIV Vaccine Trials Network
  • 116. Hoffmann-La Roche
  • 117. Hoosier Cancer Research Network
  • 118. Huabo Biopharm
  • 119. i3 Research
  • 120. IBA Lifesciences
  • 121. Idera Pharmaceuticals
  • 122. Imperial College London
  • 123. Incheon St.Mary's Hospital
  • 124. Infectious Disease Research Institute
  • 125. inqaba biotec™
  • 126. INSYS Therapeutics
  • 127. Integrated DNA Technologies
  • 128. International AIDS Vaccine Initiative
  • 129. Ionis Pharmaceuticals
  • 130. Irvine Pharmaceutical Services
  • 131. Isarna Therapeutics
  • 132. James P. Wilmot Cancer Center
  • 133. Janssen Research & Development
  • 134. Johns Hopkins University
  • 135. Kainuu Central Hospital
  • 136. Kaneka Eurogentec
  • 137. Kanta-Hame Central Hospital
  • 138. KareBay Biochem
  • 139. Koram Biotech
  • 140. Kuopio University Hospital
  • 141. Kymenlaakso Central Hospital Kotka Finland
  • 142. Lonza
  • 143. LubioScience
  • 144. M.D. Anderson Cancer Center
  • 145. Maastricht University Medical Center
  • 146. Mario Negri Institute for Pharmacological Research
  • 147. Mary Crowley Cancer Research
  • 148. Massachusetts General Hospital
  • 149. MBC BioLabs
  • 150. MBiotech
  • 151. Medigene
  • 152. MedImmune
  • 153. Merck
  • 154. Microsynth
  • 155. Midland Certified Reagent
  • 156. Mikkeli Central Hospital
  • 157. Mina Alpha
  • 158. miRagen Therapeutics
  • 159. Moligo Technologies
  • 160. National Cancer Institute
  • 161. National Cancer Institute of Canada - Clinical Trials Group
  • 162. National Eye Institute
  • 163. National Heart, Lung, and Blood Institute
  • 164. National Institute of Allergy and Infectious Diseases
  • 165. National Institute of Diabetes and Digestive and Kidney Diseases
  • 166. National Institutes of Health
  • 167. National Institutes of Health Clinical Center
  • 168. Nitto Denko Avecia
  • 169. Novatia
  • 170. NOXXON Pharma
  • 171. NYU Langone Health
  • 172. NZYTech
  • 173. Oligomer
  • 174. OliX Pharmaceuticals
  • 175. Ophthotech
  • 176. OPKO Health
  • 177. Orphan Disease Treatment Institute
  • 178. Osaka International Cancer Institute
  • 179. Osaka Prefectural Hospital Organization
  • 180. Oulu University Hospital
  • 181. Pennington Biomedical Research Center
  • 182. Pfizer
  • 183. PharmaMar
  • 184. Pharmaxis
  • 185. Primetech
  • 186. ProQR Therapeutics
  • 187. Quark Pharmaceuticals
  • 188. Quintara Biosciences
  • 189. R&D Kanglin Biotech
  • 190. Radboud University
  • 191. Regulus Therapeutics
  • 192. RemeGen
  • 193. ReNetX Bio
  • 194. ReproCell
  • 195. Retina Institute of Hawaii
  • 196. Retinal Consultants of Arizona
  • 197. RiboBio
  • 198. Rockland Immunochemicals
  • 199. Ruibo Bio-Technology
  • 200. RXi Pharmaceuticals
  • 201. Samuel Lunenfeld Research Institute, Mount Sinai Hospital
  • 202. Sanofi
  • 203. Santaris Pharma
  • 204. Sarepta Therapeutics
  • 205. Satakunta Central Hospital
  • 206. Scandinavian Gene Synthesis
  • 207. Science Exchange
  • 208. Severn Biotech
  • 209. Shanghai Public Health Clinical Center
  • 210. Shanghai Zerun Biotechnology
  • 211. Sierra Oncology
  • 212. Sigma Aldrich
  • 213. Silence Therapeutics
  • 214. Silenseed
  • 215. Sirna Therapeutics
  • 216. SomaLogic
  • 217. ST Pharm
  • 218. STA Pharmaceuticals
  • 219. Stanford University
  • 220. Statens Serum Institut
  • 221. Sterna Biologicals
  • 222. Sumitomo Chemical
  • 223. Sunomix Biosciences
  • 224. Sylentis
  • 225. Synbio Technologies
  • 226. Syngene International
  • 227. Tacere Therapeutics
  • 228. TAG Copenhagen
  • 229. Takara Bio USA
  • 230. Tampere University Hospital
  • 231. Tectron
  • 232. The Medicines Company
  • 233. The University of Texas Health Science Center at San Antonio
  • 234. Thermo Fisher Scientific
  • 235. TIMI Study Group
  • 236. TriLink Biotechnologies
  • 237. Tsinghua University
  • 238. Turku University Hospital
  • 239. UNC Lineberger Comprehensive Cancer Center
  • 240. Universitaire Ziekenhuizen Leuven
  • 241. University of Chicago
  • 242. University of Michigan Rogel Cancer Center
  • 243. University of Munich
  • 244. University of Oxford
  • 245. University of Pennsylvania
  • 246. University of Pittsburgh
  • 247. University of Rochester
  • 248. University of Toronto
  • 249. ValueGene
  • 250. Vivantis Technologies
  • 251. VWR
  • 252. Wake Forest University
  • 253. Wave Life Sciences
  • 254. Wings Therapeutics
  • 255. Winthrop University Hospital
  • 256. Xcelris
  • 257. ZonMw
Back to Top